Other
Common Stock, Shares, Outstanding
Neurocrine Biosciences Common Stock, Shares, Outstanding increased by 0.5% to $100.6M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 1.6%, from $99M to $100.6M. Over 5 years (FY 2020 to FY 2025), Common Stock, Shares, Outstanding shows relatively stable performance with a 1.4% CAGR.
Analysis
StatementBalance Sheet Statement
SectionOther
First reportedQ4 2019
Last reportedQ1 2026May 5, 2026
Metric ID:
other_common_stock_shares_outstandingHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $94.6M | $94.8M | $94.9M | $95.5M | $95.6M | $96.1M | $96.5M | $97.5M | $97.6M | $98.2M | $98.7M | $100.6M | $100.9M | $101.2M | $99.4M | $99M | $99M | $99.7M | $100.1M | $100.6M |
| QoQ Change | — | +0.2% | +0.1% | +0.6% | +0.1% | +0.5% | +0.4% | +1.0% | +0.1% | +0.6% | +0.5% | +1.9% | +0.3% | +0.3% | -1.8% | -0.4% | +0.0% | +0.7% | +0.4% | +0.5% |
| YoY Change | — | — | — | — | +1.1% | +1.4% | +1.7% | +2.1% | +2.1% | +2.2% | +2.3% | +3.2% | +3.4% | +3.1% | +0.7% | -1.6% | -1.9% | -1.5% | +0.7% | +1.6% |
Range$94.6M – $101.2M
CAGR+1.3%
Avg YoY Growth+1.3%
Median YoY Growth+1.7%
Current Streak4 quarters growth
Common Stock, Shares, Outstanding at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's common stock, shares, outstanding?
- Neurocrine Biosciences (NBIX) reported common stock, shares, outstanding of $100.6M in Q1 2026.
- How has Neurocrine Biosciences's common stock, shares, outstanding changed year-over-year?
- Neurocrine Biosciences's common stock, shares, outstanding increased by 1.6% year-over-year, from $99M to $100.6M.
- What is the long-term trend for Neurocrine Biosciences's common stock, shares, outstanding?
- Over 5 years (2020 to 2025), Neurocrine Biosciences's common stock, shares, outstanding has grown at a 1.4% compound annual growth rate (CAGR), from $93.5M to $100.1M.